Discover The Latest Treatment for Tinnitus!
For the estimated 10–15% of adults worldwide living with chronic tinnitus, 2025 has brought meaningful progress in tinnitus treatment. After decades of limited approaches, bimodal neuromodulation devices such as the Lenire device have received regulatory approval, while new brain-based research is changing how professionals view tinnitus symptoms and potential therapies.
Lenire® treatment for tinnitus is a relatively new approach that uses bimodal stimulation (tongue and ears) to reduce tinnitus.
As a specialist tinnitus clinic, we’re committed to keeping our community informed with the latest research and clinical trial results — so you know exactly what works and why.
FDA-Approved Bimodal Neuromodulation: The Lenire Device
The Lenire device received FDA approval in 2023, marking the first time a bimodal neuromodulation device was authorised for the treatment of tinnitus. The company behind Lenire is Ireland-based, and it initially focused on North America as its biggest opportunity for its device.
Lenire uses sound therapy delivered through wireless headphones combined with mild electrical stimulation in the form of pulses applied to the tongue. This approach, known as bimodal stimulation, aims to retrain the brain’s processing of tinnitus sounds. The technique works by stimulating the somatosensory nerves and the auditory nerve together, encouraging adaptive brain plasticity that reduces tinnitus prominence.
Key aspects of Lenire treatment include:
- Sound and tongue stimulation are delivered simultaneously
- Different bimodal neuromodulation settings adjusted to individual needs
- Daily at-home use of the treatment device for around 60 minutes
- Regular monitoring from a trained tinnitus specialist
While promising, this option is currently available only through a limited number of tinnitus clinics in the UK.
Clinical Trials and Evidence to Improve Quality of Life
Several in-house clinical trials have been conducted on Lenire. Lenire’s clinical trials involving more than 600 tinnitus patients (including the TENT-A1, TENT-A2, and TENT-A3 studies) show encouraging results in treating tinnitus symptoms. However, in-house studies carry much less weight in terms of validity than academic, independent research trials.
For example, clinical trial data from TENT-A3 demonstrated a higher response rate among patients receiving bimodal neuromodulation combining sound and tongue stimulation compared with sound therapy alone. Treatment-compliant participants reported significant improvements in tinnitus severity, quality of life, and reductions in emotional distress.
Some key findings include:
- Improvements measured on the Tinnitus Handicap Inventory and Tinnitus Functional Index
- Over 90% of compliant patients in certain studies reported measurable benefit
- Long-term improvements were maintained for up to 12 months post-treatment
It is important to note that results vary, and success depends on patient compliance criteria such as consistent daily use of the treatment device.
Brain-Based Approaches to Treat Tinnitus
Beyond devices like Lenire, new research is exploring how tinnitus may be linked to neurological processes in the brain. This view considers severe tinnitus not just as an ear-related problem but as part of abnormal sensory integration within the central nervous system.
Other bimodal devices are due to be on the market within the coming year and research continues to grow in the field of tinnitus.
Emerging treatment options in specialist settings include:
- Medications for migraine-related tinnitus mechanisms
- Supplements targeting neuroinflammation
- Cognitive behavioural therapy adapted for neuroplastic retraining
- Personalised sound stimulation calibrated to individual hearing thresholds
- Lifestyle strategies to reduce stress and worse tinnitus flare-ups
These approaches are still under investigation, and their availability applies solely to research centres and advanced clinics.
Suitability and Patient Selection for Lenire Treatment
The Lenire device and similar neuromod devices are generally intended for adults with moderate or worse tinnitus lasting at least three months. Ideal candidates are those with persistent, severe tinnitus who have not responded to more traditional strategies.
Patients with pulsatile tinnitus, objective tinnitus, ear infection, temporomandibular joint disorder, or recent neck injury may not be suitable. Each patient requires a full hearing test, medical history review, and assessment of tinnitus severity before starting treatment.
Costs and Accessibility
In the UK, the cost of a full Lenire treatment programme is currently estimated at £3,500 -£4000, covering the treatment device, initial fitting, and follow-up visits. Costs may vary by clinic, and insurance coverage differs across regions.
For many, this cost is prohibitive and it is hoped that less expensive treatment options become availabel over the coming years.
What These Developments Mean for Patients
The latest treatments do not claim to cure tinnitus but aim to provide relief by reducing tinnitus to a more manageable level. For many tinnitus patients, the goal is to lessen the impact of tinnitus symptoms on daily life and improve overall quality of life. Find out how audilogists test for tinnitus.
What is needed for any new treatment option however is robust, independent research. CBT approaches for tinnitus at present remains teh most validated treatement option for tinnitus.
Final Thoughts
At The Hearing Space tinnitus clinic, we provide a full range of evidence-based solutions — from hearing tests, hearing aids, and sound therapy to CBT tinnitus support programmes.
For anyone experiencing chronic tinnitus or severe cases of tinnitus, the first step is a professional assessment. Understanding your symptoms, any related hearing loss, and how tinnitus affects daily life is key to creating a treatment plan that works. Our goal is to empower patients with clear options and the latest knowledge to support long-term hearing health.